Anti-Cd19/Cd22 Car-T Cells
Acute Lymphoblastic Leukemia, Adult B-Cell
Essen BiotechCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Acute Lymphoblastic Leukemia, Adult B-Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
cd19-ucart The General Hospital of Western Theater Command | Phase 1 | CCC |
Sscart-19 The First Affiliated Hospital of Soochow University | Phase 1/2 | CC |
Cart-19 Cells The First Affiliated Hospital of Soochow University | Phase 1/2 | CC |
cd22 car-transduced t cells Essen Biotech | Phase 1/2 | CC |
trx103 Tr1X, Inc. | Phase 1 | CC |
Same molecule, other indications
Anti-Cd19/Cd22 Car-T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →